article thumbnail

STAT+: Pharmalittle: Weight-loss drug ads pose new oversight challenge; will the new Bayer CEO split the company?

STAT

They may involve infusions of a gene packaged inside the shell of a virus, which can lead to potential immune complications and can require close monitoring of patients. Promising therapies for some diseases are administered through lumbar punctures, which are not a routine part of a doctor’s daily practice.

Packaging 246
article thumbnail

FDA declines Eli Lilly’s bowel disease drug over manufacturing issues

Pharmafile

However, concerns weren’t expressed over the clinical data package, safety or label for the medicine. Mirikizumab was hoped to become a new drug treatment for ulcerative colitis (UC), a condition where abnormal reactions in the immune system cause inflammation in the inner lining of the colon. read more

Packaging 119
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

New antibody could be promising cancer treatment

World Pharma News

Researchers have developed a unique type of antibody that both targets and delivers a drug package via the antibody itself, while simultaneously activating the immune system ("3-in-1 design") for personalised immunotherapy treatments. The study has been published in Nature Communications.

article thumbnail

CanSinoBIO developed a highly effective COVID vaccine with an inhalant version

pharmaphorum

It then elicits an immune response against that spike protein. Morgon says CanSinoBIO produced an inhalant version of Convidencia because an immune response called mucosal immunity is triggered in addition to the circulating antibodies and the T cell response. There’s no additional replication in the person.

Vaccines 138
article thumbnail

Nitrogen dioxide for sterilisation of protein-filled polymer-based syringes

European Pharmaceutical Review

Researchers have shown that nitrogen dioxide (NO 2 ) gas sterilisation may be the most appropriate choice for the sterilisation of intravitreal injections (IVIs) packaged in polymer-based prefilled syringes (P-PFSs).

article thumbnail

September 2023 Newsletter

Safe Biologics

6 would prevent the HHS Secretary from requiring a switching study as part of the data package to receive the interchangeable designation. The product is an interleukin-6 (IL-6) receptor antagonist that targets specific inflammatory proteins to suppress the immune system. However, S.6 ASBM surveys of U.S.

article thumbnail

iOnctura and Clavius exercise option for TGF-? pathway inhibitor

Pharmaceutical Technology

It will help the firm target therapy resistance and immune evasion pathways, along with IOA-359’s direct impact on the tumour. The grant will see the use of UT’s model system to help iOnctura with a preclinical pharmacology package for IOA-359 in cancer. iOnctura will exclusively develop and commercialise IOA-359 across the globe.